Evidence map›Paper›PMID 39584843›Full record

ArticleInfectious disease reports2024

Proprotein Convertase Subtilisin Kexin 9 Inhibitor in Severe Sepsis and Septic Shock Patients in a Phase II Prospective Cohort Study-Preliminary Results.

Ziv Rosman, Yasmin Maor, Iris Zohar, Gingy Ronen Balmor, Miri Schamroth Pravda, Adam Lee Goldstein, Milena Tocut, Arie Soroksky

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infectious disease reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ziv RosmanIntensive Care Department, E. Wolfson Medical Center, Holon 5822012, Israel.ORCID 0000-0002-1344-6875
Yasmin MaorFaculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.ORCID 0000-0001-7258-3434
Iris ZoharFaculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.ORCID 0009-0004-5470-2208
Gingy Ronen BalmorIntensive Care Department, E. Wolfson Medical Center, Holon 5822012, Israel.
Miri Schamroth PravdaIntensive Care Department, E. Wolfson Medical Center, Holon 5822012, Israel.
Adam Lee GoldsteinSurgical Department A Trauma Division, E. Wolfson Medical Center, Holon 5822012, Israel.
Milena TocutFaculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
Arie SorokskyIntensive Care Department, E. Wolfson Medical Center, Holon 5822012, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sepsis is a life-threatening organ dysfunction syndrome caused by a dysregulated host response to infection that has a high mortality rate. Proprotein convertase subtilisin kexin 9 (PCSK9) is a serine protease secreted by the liver. Its binding to the low-density lipoprotein (LDL) receptor enhances its degradation, causing an increase in LDL levels in the blood.

Indexed as

alirocumabPCSK9 inhibitorsepsisseptic shock

Identifiers

PMID39584843
PMCPMC11586949

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.